Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Vertex Pharmaceuticals Inc

+ Add to Watchlist

VRTX:US

120.3400 USD 2.7400 2.33%

As of 20:10:00 ET on 03/27/2015.

Snapshot for Vertex Pharmaceuticals Inc (VRTX)

Open: 117.7300 Day's Range: 117.4500 - 120.7800 Volume: 1,618,094
Previous Close: 117.6000 52wk Range: 59.7900 - 136.3300 1-Yr Rtn: +77.49%

Stock Chart for VRTX

No chart data available.
  • VRTX:US 120.3400
  • 1D
  • 1M
  • 1Y
117.6000
Interactive VRTX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VRTX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -2.7581
Est. EPS (USD) (12/2015) -0.8960
Est. PEG Ratio -
Market Cap (M USD) 29,132.98
Shares Outstanding (M) 242.09
30 Day Average Volume 1,841,184
Price/Book (mrq) 27.0640
Price/Sale (ttm) 48.8133
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VRTX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for VRTX

Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is developing drugs for the treatment of viral diseases, multidrug resistance in cancer, inflammatory and autoimmune diseases, and neurodegenerative diseases.

Jeffrey M Leiden "Jeff"Chairman/President/CEOIan F SmithExec VP/CFO
Stuart A ArbuckleExec VP/Chief Commercial OfcrDavid AltshulerExec VP:Global Research
More Company Profile & Key Executives for VRTX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil